Nasdaq:US$15.72 (+0.06) | HKEX:HK$24.75 (+0.75) | AIM:£2.47 (+0.03)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)